Effectiveness of Tirofiban, Eptifibatide, and Abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)

Annapoorna S. Kini, Merwin Richard, Javed Suleman, Nohelia Perez, Paul Lee, Edward A. Fisher, Mazullah Kamran, Jonathan D. Marmur, Samin K. Sharma

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

The TEAM pilot study underscores the importance of adequate platelet inhibition (>90% PI) in high-risk PCI, and demonstrates that attaining >90% PI is possible in most patients by adding a half-bolus of any GP IIb/IIIa inhibitor, with no increase in major/minor bleeding similar periprocedural myocardial necrosis, and 30-day MACE with all 3 GP IIb/IIIa inhibitors.

Original languageEnglish
Pages (from-to)526-529
Number of pages4
JournalAmerican Journal of Cardiology
Volume90
Issue number5
DOIs
StatePublished - 1 Sep 2002

Fingerprint

Dive into the research topics of 'Effectiveness of Tirofiban, Eptifibatide, and Abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)'. Together they form a unique fingerprint.

Cite this